Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

Benzinga Newsdesk www.benzinga.com Positive 88.8%

Neg 0% Neu 0% Pos 88.8%

Evercore ISI Group analyst Cory Kasimov initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $25.